Exenatide induces autophagy and prevents the cell regrowth in HepG2 cells

Main Article Content

Gabriele Catyana Krause
Kelly Goulart Lima
Vitor Levorse
Gabriela Viegas Haute
Rodrigo Benedetti Gassen
Maria Cláudia Garcia
Leonardo Pedrazza
Márcio Vinícius Fagundes Donadio
Carolina Luft
Jarbas Rodrigues de Oliveira


The incidence of hepatocellular carcinoma (HCC) keeps rising year by year, and became the second leading cause of cancer-related death. Some studies have found that liraglutide, a GLP-1 analog, may decrease the tumor cells proliferation. Due to this, the aim of this work is to investigate the antiproliferative potential of exenatide, another GLP-1 analog. Cell proliferation was assessed by direct count with Trypan blue dye exclusion. Flow cytometry was used to determinate autophagy and nuclear staining. Morphometric analysis was used to verify senescence and apoptosis. The mechanism that induced cell growth inhibition was analyzed by Western Blot. Treatment with exenatide significantly decreases cell proliferation and increases autophagy, both in relation to control and liraglutide. In addition, mTOR inhibition was greater in cells treated with exenatide. In relation to chronic treatment, exenatide does not allow cellular regrowth by preventing some resistance mechanism that the cells can acquire. These results suggest that exenatide has a potent anti-proliferative activity via mTOR modulation and, among the GLP-1 analogs tested, could be in the future an alternative for HCC treatment.

Article Details

How to Cite
Krause, G., Lima, K., Levorse, V., Haute, G., Gassen, R., Garcia, M., Pedrazza, L., Donadio, M. V., Luft, C., & de Oliveira, J. (2019). Exenatide induces autophagy and prevents the cell regrowth in HepG2 cells. EXCLI Journal, 18, 540-548. https://doi.org/10.17179/excli2019-1415
Original articles